ASSESSMENT OF LIVER FUNCTION IN PATIENTS UNDERGOING HEPATIC IRRADIATION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究是为了评估吲哚青绿(IC-Green)在放射过程中确定肝功能的使用情况。他们认为，如果我们能更好地估计个体的毒性风险，就可以在并发症发生之前停止对高并发症风险患者的放射治疗。参加这项研究的受试者必须是18岁或以上。不会因性别、种族或种族而被排除在外。孕妇将被排除在参与之外。这项研究是为了评估吲哚青绿(IC-Green)在放射过程中确定肝功能的使用情况。他们认为，如果我们能更好地估计个体的毒性风险，就可以在并发症发生之前停止对高并发症风险患者的放射治疗。参加这项研究的受试者必须是18岁或以上。不会因性别、种族或种族而被排除在外。孕妇将被排除在参与之外。参与这项研究的患者需要安排接受肝脏放射治疗。在这项研究中，它们将在放射治疗开始前2周内接受IC-Green测试，剂量约为20-27，约32-54，辐射后约1个月，辐射后约2个月。在静脉注射IC-Green后5分钟、10分钟、15分钟和20分钟采集血样。该试验的目的是评估IC-Green萃取法确定的放射治疗对肝功能的影响。研究人员认为，如果他们能够确定接受肝脏放射治疗的患者可能会出现严重副作用的可能性，那么在并发症发生之前，那些风险最高的患者就可以停止放射。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research is being conducted to assess the use of indocyanine green (IC-Green) to determine liver function during a course of radiation. The belief is that if we can better estimate the risk of toxicity on an individual basis that radiation can be stopped in patients at high risk for complications before the complications occur. Subjects who take part in this research must be 18 or older. No exclusion will be made based on gender, ethnicity or race. Pregnant women will be excluded from participating. This research is being conducted to assess the use of indocyanine green (IC-Green) to determine liver function during a course of radiation. The belief is that if we can better estimate the risk of toxicity on an individual basis that radiation can be stopped in patients at high risk for complications before the complications occur. Subjects who take part in this research must be 18 or older. No exclusion will be made based on gender, ethnicity or race. Pregnant women will be excluded from participating. Patients who take part in this study are required to be scheduled for radiation to the liver. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy, at approximately 20-27 Gy, at approximately 32-54 Gy, approximately one month after radiation, and approximately two months after radiation. Blood samples will be collected baseline 0, at 5, 10, 15, and 20 minutes following I.V. administration of IC-Green. The goal of the trial is to assess the effect of radiation treatment on liver function as determined by IC-Green extraction. The researchers believe that if they can determine the chances that a patient getting radiation to the liver might experience severe side effects that the radiation can be stopped in those patients at highest risk before the complications occur.'